An observational study in Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms, sponsored by University Hospital, Brest. Completed at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by University Hospital, Brest · Observational
Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms.
Prospective work based on the distribution of a dedicated questionnaire.
Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis.
Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus.
Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 170 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with one of three Philadelphia positive non-chromosome myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (TE) or primary myelofibrosis (PMF).
And suffering (or having suffered) from aquagenic pruritus.
Exclusion Criteria:
Description of pruritus in patients with myeloproliferative neoplasms
Intensity of pruritus (visual analogic scale)
Time frame: at the time of questionnaire completion (Day 0)
Description of therapies used to treat pruritus
Name of drugs used
Time frame: at the time of questionnaire completion (Day 0)
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Brest